Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (6156)	1/17/2000 8:48:00 AM
From: BDR	Read Replies (1) \| Respond to of 10293

HEPH, like REFR and ALTIF, will probably produce more press releases than marketable products for many years to come. Hollis-Eden Pharmaceuticals Announces Update On Investigational Drug in Preclinical Model of Malaria siliconinvestor.com

To: Bill Wexler who wrote (6156)	1/17/2000 6:26:00 PM
From: N. Dixon	Read Replies (1) \| Respond to of 10293

Bill,Kevin, and anyone else who has questions. Here is the phone number to REFR - 1-888-773-7337. They can answer all your questions. Grill them to your heart's content. Ask about every licensee, explain to them how long Xerox technology took and ask why are they taking so long, ask "where did Bob Saxe go to college," "what did Carl Lampert REALLY mean in his quote," "what do the latest deals represent and how do they differ from the prior ones" etc, etc. I have made my decision based on what I know to be true. Your conclusion, that because there have been no products there never will be, is false. Plain and simple. People that have done the due diligence are buying REFR. I told you very plainly that we expect products in 2000. We are supremely confident there will be products in 2000 and that is why we continue to buy the stock. ND